Factors associated with the use of adjuvant neratinib in stage I-III HER2-positive breast cancer.

被引：0
|
作者：
Stoen, Ericson
Kagihara, Jodi
Kabes, Pater
Fisher, Christine M.
Diamond, Jennifer Robison
机构：
[1] Univ Colorado, Sch Med, Aurora, CO USA
[2] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12517
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Adjuvant trastuzurnab therapy for HER2-Positive breast cancer
    Jahanzeb, Mohammad
    CLINICAL BREAST CANCER, 2008, 8 (04) : 324 - 333
  • [42] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
    Barcenas, C. H.
    Hurvitz, S. A.
    Di Palma, J. A.
    Bose, R.
    Chien, A. J.
    Iannotti, N.
    Marx, G.
    Brufsky, A.
    Litvak, A.
    Ibrahim, E.
    Alvarez, R. H.
    Ruiz-Borrego, M.
    Chan, N.
    Manalo, Y.
    Kellum, A.
    Trudeau, M.
    Thirlwell, M.
    Saenz, J. Garcia
    Hunt, D.
    Bryce, R.
    McCulloch, L.
    Rugo, H. S.
    Tripathy, D.
    Chan, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1223 - 1230
  • [43] Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
    Schwartz, Naomi R. M.
    Flanagan, Meghan Rose
    Babigumira, Joseph B.
    Steuten, Lotte Maria Gertruda
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
    Kourie, Hampig Raphael
    Chaix, Marie
    Gombos, Andrea
    Aftimos, Phillippe
    Awada, Ahmad
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) : 947 - 957
  • [45] The University of Florida Experience with HER2-Positive Stage I-III Breast Cancers: Is there an Increased Risk of Local-regional Recurrence?
    Swanson, E. L.
    Mendenhall, N. P.
    Morris, C. G.
    Lightsey, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S248 - S248
  • [46] Incorporating Neratinib Into Clinical Practice for Patients With HER2-Positive Metastatic Breast Cancer
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 15
  • [47] Influencing factors of the recurrence after neoadjuvant therapy in HER2-positive breast cancer.
    Murillo, Serafin Morales
    Ariadna, Gasol Cud S.
    Der-Abrain, Noemi Tuset
    Rodriguez, Alvaro
    Sanchez, Ana Velasco
    Vilardell, Felip
    Guzman, Douglas Sanchez
    Morales, Carles Canosa
    Olive, Jordi Mele
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
    Khattak, Monica N.
    Chichura, Anna M.
    Lang, Julie E.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1423 - 1427
  • [49] Use of disseminated tumor cells to predict outcome in patients with stage I-III breast cancer.
    Gainer, Sarah Marie
    Krishnamurthy, Savitri
    Bhattacharyya, Anirban
    Lodhi, Ashutosh
    Hall, Carolyn S.
    Bedrosian, Isabelle
    Kuerer, Henry Mark
    Lucci, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [50] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
    Monica N. Khattak
    Anna M. Chichura
    Julie E. Lang
    Annals of Surgical Oncology, 2024, 31 : 1423 - 1427
12345